Arcellx, INC Form 4 insider transactions

Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports the acquisition and disposal of common stock and stock options.

Director Ali Behbahani acquired stock options in Arcellx, Inc. on May 28, 2024, according to a recent SEC filing.

Director Jill Carroll reported the acquisition of stock options in Arcellx, Inc. on May 28, 2024.

Director Derek Yoon acquired stock options in Arcellx, Inc. on May 28, 2024.

Director Olivia C Ware reports acquisition of 8,011 stock options in Arcellx, Inc.

Director Kavita Patel acquired stock options in Arcellx, Inc. on May 28, 2024.

Director David Charles Lubner acquired stock options in Arcellx, Inc. on May 28, 2024.

Michelle Gilson, CFO of Arcellx, Inc., reports the acquisition and disposition of company stock related to restricted stock units.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., exercised stock options and sold shares of common stock on May 1, 2024, according to a Form 4 filing with the SEC.

Director Olivia C. Ware exercised stock options and sold shares of Arcellx, Inc. on April 16, 2024, according to a Form 4 filing with the SEC.

Arcellx CEO Rami Elghandour sold common stock in multiple transactions on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., exercised stock options and sold shares of common stock between March 22 and March 26, 2024, according to a recent SEC filing.

Director Jill Carroll sold 504,263 shares of Arcellx, Inc. at a price of $70.55 on March 21, 2024.

Arcellx's CFO, Michelle Gilson, executed sales of common stock on March 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Olivia C. Ware, a director at Arcellx, Inc., exercised stock options and sold shares of common stock on March 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.